MCM
MRNS

Moore Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Moore Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,181
Closed -$251K – 567
2023
Q3 		$251K Sell
31,181
-43,819
-58% -$365K ﹤0.01% 367
2023
Q2 		$815K Buy
+75,000
New +$642K 0.01% 320

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Moore Capital Management's MRNS Position: Q4 2023 in Review

Moore Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2023, closing a stake of 31,181 shares — an estimated $251K sold.

Moore Capital Management first reported a position in MRNS in Q2 2023 and held it in 2 quarters. The position peaked at $815K in Q2 2023. 105 funds tracked by Wall St. Rank hold MRNS as of Q4 2023.

  • Moore Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 31,181 Marinus Pharmaceuticals, Inc shares in Q4 2023, an estimated $251K.
  • Moore Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2023 and held it in 2 quarters.
  • Moore Capital Management's Marinus Pharmaceuticals, Inc position peaked at $815K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.